Because TP53 haploinsufficiency may generate genetic instability and play a crucial role in tumorigenesis [33], it is reasonable to assume that bearing single or double TP53 lesions have a minimal differential impact, if any, on the outcome with BTKi agents in this genetic subset of patients with CLL. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.